Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 11 de 11
Sexually Transmitted Diseases ; JOUR:S52-S53, 49(10 Supplement 1).
Article in English | EMBASE | ID: covidwho-2092707


BACKGROUND: The COVID-19 pandemic severely diminished the capacity of sexual health programs and clinics through clinic closures, staff redeployment, and significant reductions in routine, asymptomatic STI screening, spurring innovations in the field including non-clinic-based, self-collect STI testing. In response to these innovations and feedback from the field, NCSD partnered with Let'sGetChecked, a commercial lab and technology company, to create a public health solution for non-clinic-based, self-collect STI testing, CheckYourself, which launched its pilot phase in January 2022. METHOD(S): In January of 2022, CheckYourself launched its pilot phase of the program with a Standard 5 test kit [HIV (I, II, P24 antigen), Syphilis EIA, urine GC, CT, and Trichomoniasis] at five public health sites: Los Angeles County Department of Public Health, Philadelphia Department of Health, Iowa Department of Public Health, Oklahoma Department of Public Health, and Navajo County Department of Public Health. RESULT(S): Pilot sites implemented one or both of the following workflows: 1) bulk test kit shipment utilized by DIS for contacts, at health fairs, or by sexual health clinics for clients who present to clinics who have reached capacity for the day;2) provider-initiated test kits sent overnight to clients after a telehealth consultation. At least one clinic utilized bulk shipment test kits for persons seeking a pregnancy test at the public health department. Data and analysis on client and health department satisfaction with program, utilization, positivity rate, time from test order to results, etc., is forthcoming and will be available by the conference. CONCLUSION(S): CheckYourself is the first-ever non-clinic-based, self-collect STI testing solution that was developed by, for, and in partnership with public health departments to reduce barriers to asymptomatic STI screening.

Sexually Transmitted Diseases ; 49(10S):S127-S128, 2022.
Article in English | Web of Science | ID: covidwho-2068173
British Journal of Surgery ; 108:1, 2021.
Article in English | Web of Science | ID: covidwho-1539394
British Journal of Surgery ; 108:216-216, 2021.
Article in English | Web of Science | ID: covidwho-1539381
British Journal of Surgery ; 108(SUPPL 2):ii21, 2021.
Article in English | EMBASE | ID: covidwho-1254452


Background: The United Kingdom now has one of the highest death rates from COVID 19, with over 40,000 deaths (1). It has been posited that the identification of care workers with immunity or increased resistance could be important in developing future strategies. Method: This was a retrospectively conducted survey of general surgical staff at a tertiary surgical unit. Results: We surveyed 215 staff that had undergone antibody testing. Of the 175/215 who reported contact with COVID-19 positive patients, 6/ 215 had a positive PCR result and 15/215 reported a positive antibody test. Only 3/6 that had a positive PCR test demonstrated antibodies. Conclusions: Our immunity rate of 7% is extremely low and is concerning especially in respect of the anticipated herd immunity which would mitigate many of the issues presently being confronted and it is likely to be many months at least before this makes realistic contribution. Continued testing for the presence of COVID-19 antibodies will contribute to crucial seroprevalence data that can be used by public health bodies whose advice will necessarily evolve as increasing data sets become available.